[ad_1] Natco Gets SC Nod to Launch Generic Risdiplam at 80% Lower Price, Roche Appeal Dismissed We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] The Supreme Court on Friday cleared decks for Natco Pharma to launch its generic version of the drug Risdiplam in India, even as it dismissed Swiss drugmaker F. Hoffmann-La Roche’s appeal seeking to restrain the Hyderbad firm. Risdiplam is an oral medicine used for spinal muscular atrophy (SMA) in patients two months or older…
[ad_1] F. Hoffmann-La Roche AG on Tuesday moved the Supreme Court against a Delhi High Court’s order that allowed Natco Pharma to launch a generic version of the drug Risdiplam in India. Risdiplam is an oral medicine used for spinal muscular atrophy (SMA) in patients two months or older. Roche’s counsel sought urgent listing of…
[ad_1] Delhi HC Dismisses Roche Appeal, Allows Natco to Continue Selling Generic Risdiplam for Spinal Muscular Atrophy We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Mumbai: In a landmark ruling, an appellate bench of the Delhi High Court on Wednesday sided with Hyderabad-based Natco Pharma over a long-drawn patent battle involving Swiss biotech giant Roche‘s rare disease drug risdiplam made available in India under the brand name Evrysdi. A leading expert on patents and intellectual property rights told ET…
[ad_1] A division bench of the Delhi High Court on Thursday allowed Natco Pharma to launch the drug risdiplam in India, even as it rejected Swiss multinational F. Hoffmann-La Roche AG’s plea seeking to the contrary. The bench led by Justice Hari Shankar vacated its March order that had asked Hyderabad-based Natco Pharma to maintain…